• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RVA
Click for more information
0.00% 0.0¢

REVA MEDICAL, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
RVANotice of Briefing Call06/11/13
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/10/13
RVAImplant & Pilot Trial Update Presentation at TCT ConferencePRICE SENSITIVE30/10/13
RVAPresentation at TCT 2013 Conference28/10/13
RVAPresentation at Polymers in Medicine and Biology Conference10/10/13
RVALive Case Implant at ANZET Meeting09/08/13
RVAHalf Yearly Report and Accounts (Appendix 4D)PRICE SENSITIVE09/08/13
RVANotice of Briefing Call & Canaccord Conference Presentation07/08/13
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/07/13
RVAClinical Trial Expanded to Australia and New ZealandPRICE SENSITIVE27/06/13
RVAPresentation at Wells Fargo Healthcare Conference14/06/13
RVAAppendix 3B05/06/13
RVAChange of Director's Interest Notice04/06/13
RVAChange of Director's Interest Notice04/06/13
RVAChange of Director's Interest Notice04/06/13
RVAChange of Director's Interest Notice04/06/13
RVAChange of Director's Interest Notice04/06/13
RVAChange of Director's Interest Notice04/06/13
RVAClarification of AGM Results03/06/13
RVAAGM Results30/05/13
RVAAGM Presentation30/05/13
RVA12-month Data from RESTORE Trial at EuroPCRPRICE SENSITIVE21/05/13
RVAAGM Dial-In Details16/05/13
RVAAppointment of Managing Director International14/05/13
RVAQuarterly Report on Form 10-Q09/05/13
RVAAppendix 4C - quarterlyPRICE SENSITIVE30/04/13
RVAProxy Statement for 2013 AGM19/04/13
RVAReZolve2 Clinical Trial InitiationPRICE SENSITIVE28/03/13
RVAForm S-8 Filed with SEC01/03/13
RVANotice of Briefing Call & Cowen HC Conference Presentation28/02/13
RVAPreliminary Final ReportPRICE SENSITIVE28/02/13
RVAPresentation at CRT Conference21/02/13
RVALetter to Shareholders07/02/13
RVAAppendix 3B04/02/13
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/01/13
RVAAppendix 3B22/01/13
RVARelease of Securities from Mandatory Escrow22/01/13
RVAPresentation at J.P. Morgan Conference11/01/13
RVAPresentation at Piper Jaffray Health Care Conference21/11/12
RVAQuarterly Report on Form 10-Q09/11/12
RVANotice of Briefing Call06/11/12
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
RVAEarly Follow-up Imaging Assessment of ReZolve Scaffold25/10/12
RVAPresentation at TCT ConferencePRICE SENSITIVE24/10/12
RVAChange of Director's Interest Notice17/09/12
RVADr. David Muller is Appointed Co-Principal Investigator13/09/12
RVAAppendix 3B31/08/12
RVAChange of Director's Interest Notice28/08/12
RVAHalf Yearly Report and Accounts (Appendix 4D)PRICE SENSITIVE10/08/12
RVANotice of Briefing Call09/08/12
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/07/12
RVAAppendix 3B26/07/12
RVAInitial Clinical Enrollment of ReZolve is CompletedPRICE SENSITIVE13/07/12
RVAPresentation at Wells Fargo Healthcare Conference19/06/12
RVAChange of Director's Interest Notice18/06/12
RVAChange of Director's Interest Notice08/06/12
RVAChange of Director's Interest Notice01/06/12
RVAAppendix 3B31/05/12
RVAChange of Director's Interest Notice29/05/12
RVAChange of Director's Interest Notice24/05/12
RVAChange of Director's Interest Notice24/05/12
RVAChange of Director's Interest Notice24/05/12
RVAChange of Director's Interest Notice24/05/12
RVAChange of Director's Interest Notice24/05/12
RVAAGM Results21/05/12
RVAAGM Presentation21/05/12
RVAREVA Medical Announces Interim Clinical Results at EuroPCRPRICE SENSITIVE17/05/12
RVAAGM Dial-In Details11/05/12
RVAQuarterly Report on Form 10-Q11/05/12
RVAProxy Statement and Notice of 2012 AGM01/05/12
RVAAppendix 4C - quarterlyPRICE SENSITIVE30/04/12
RVAPrivate Transaction Closes/Substantial Holder Change Notice04/04/12
RVAChange in substantial holding04/04/12
RVAPrivate Transactions for $17.6M/Substantial Holder Notices27/03/12
RVAChange in substantial holding27/03/12
RVABecoming a substantial holder27/03/12
RVAChange in substantial holding27/03/12
RVAChange in substantial holding27/03/12
RVAChange in substantial holding27/03/12
RVAShareholder Newsletter23/03/12
RVAInstitutions Agree to Acquire REVA SharesPRICE SENSITIVE19/03/12
RVAAppendix 3B16/03/12
RVAPresentations at PCR Focus Group09/03/12
RVAForm S-8 Filed with SEC02/03/12
RVAPresentation at Polymers in Medical Applications Conference01/03/12
RVABriefing Call Telephone Number01/03/12
RVAPreliminary Final ReportPRICE SENSITIVE29/02/12
RVAPresentations at Citi and ASX New York Conferences23/02/12
RVANotice of Briefing Call23/02/12
RVAClinical Trial UpdatePRICE SENSITIVE17/02/12
RVAAppendix 3B10/02/12
RVAPresentations at CRT and LDDR Conferences01/02/12
RVAAppendix 4C - quarterlyPRICE SENSITIVE31/01/12
RVAAppendix 3B20/01/12
RVAPresentation at J.P. Morgan Conference11/01/12
RVAAmended Appendix 3B x 223/12/11
RVAREVA Commences Clinical TrialPRICE SENSITIVE22/12/11
RVAExpansion of Facilities25/11/11
RVAPresentation at Piper Jaffray Health Care Conference22/11/11
RVAQuarterly Report on Form 10-QPRICE SENSITIVE15/11/11
RVANotice of Briefing Call
06/11/13
RVAAppendix 4C - quarterly
31/10/13PRICE SENSITIVE
RVAImplant & Pilot Trial Update Presentation at TCT Conference
30/10/13PRICE SENSITIVE
RVAPresentation at TCT 2013 Conference
28/10/13
RVAPresentation at Polymers in Medicine and Biology Conference
10/10/13
RVALive Case Implant at ANZET Meeting
09/08/13
RVAHalf Yearly Report and Accounts (Appendix 4D)
09/08/13PRICE SENSITIVE
RVANotice of Briefing Call & Canaccord Conference Presentation
07/08/13
RVAAppendix 4C - quarterly
31/07/13PRICE SENSITIVE
RVAClinical Trial Expanded to Australia and New Zealand
27/06/13PRICE SENSITIVE
RVAPresentation at Wells Fargo Healthcare Conference
14/06/13
RVAAppendix 3B
05/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAChange of Director's Interest Notice
04/06/13
RVAClarification of AGM Results
03/06/13
RVAAGM Results
30/05/13
RVAAGM Presentation
30/05/13
RVA12-month Data from RESTORE Trial at EuroPCR
21/05/13PRICE SENSITIVE
RVAAGM Dial-In Details
16/05/13
RVAAppointment of Managing Director International
14/05/13
RVAQuarterly Report on Form 10-Q
09/05/13
RVAAppendix 4C - quarterly
30/04/13PRICE SENSITIVE
RVAProxy Statement for 2013 AGM
19/04/13
RVAReZolve2 Clinical Trial Initiation
28/03/13PRICE SENSITIVE
RVAForm S-8 Filed with SEC
01/03/13
RVANotice of Briefing Call & Cowen HC Conference Presentation
28/02/13
RVAPreliminary Final Report
28/02/13PRICE SENSITIVE
RVAPresentation at CRT Conference
21/02/13
RVALetter to Shareholders
07/02/13
RVAAppendix 3B
04/02/13
RVAAppendix 4C - quarterly
31/01/13PRICE SENSITIVE
RVAAppendix 3B
22/01/13
RVARelease of Securities from Mandatory Escrow
22/01/13
RVAPresentation at J.P. Morgan Conference
11/01/13
RVAPresentation at Piper Jaffray Health Care Conference
21/11/12
RVAQuarterly Report on Form 10-Q
09/11/12
RVANotice of Briefing Call
06/11/12
RVAAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
RVAEarly Follow-up Imaging Assessment of ReZolve Scaffold
25/10/12
RVAPresentation at TCT Conference
24/10/12PRICE SENSITIVE
RVAChange of Director's Interest Notice
17/09/12
RVADr. David Muller is Appointed Co-Principal Investigator
13/09/12
RVAAppendix 3B
31/08/12
RVAChange of Director's Interest Notice
28/08/12
RVAHalf Yearly Report and Accounts (Appendix 4D)
10/08/12PRICE SENSITIVE
RVANotice of Briefing Call
09/08/12
RVAAppendix 4C - quarterly
31/07/12PRICE SENSITIVE
RVAAppendix 3B
26/07/12
RVAInitial Clinical Enrollment of ReZolve is Completed
13/07/12PRICE SENSITIVE
RVAPresentation at Wells Fargo Healthcare Conference
19/06/12
RVAChange of Director's Interest Notice
18/06/12
RVAChange of Director's Interest Notice
08/06/12
RVAChange of Director's Interest Notice
01/06/12
RVAAppendix 3B
31/05/12
RVAChange of Director's Interest Notice
29/05/12
RVAChange of Director's Interest Notice
24/05/12
RVAChange of Director's Interest Notice
24/05/12
RVAChange of Director's Interest Notice
24/05/12
RVAChange of Director's Interest Notice
24/05/12
RVAChange of Director's Interest Notice
24/05/12
RVAAGM Results
21/05/12
RVAAGM Presentation
21/05/12
RVAREVA Medical Announces Interim Clinical Results at EuroPCR
17/05/12PRICE SENSITIVE
RVAAGM Dial-In Details
11/05/12
RVAQuarterly Report on Form 10-Q
11/05/12
RVAProxy Statement and Notice of 2012 AGM
01/05/12
RVAAppendix 4C - quarterly
30/04/12PRICE SENSITIVE
RVAPrivate Transaction Closes/Substantial Holder Change Notice
04/04/12
RVAChange in substantial holding
04/04/12
RVAPrivate Transactions for $17.6M/Substantial Holder Notices
27/03/12
RVAChange in substantial holding
27/03/12
RVABecoming a substantial holder
27/03/12
RVAChange in substantial holding
27/03/12
RVAChange in substantial holding
27/03/12
RVAChange in substantial holding
27/03/12
RVAShareholder Newsletter
23/03/12
RVAInstitutions Agree to Acquire REVA Shares
19/03/12PRICE SENSITIVE
RVAAppendix 3B
16/03/12
RVAPresentations at PCR Focus Group
09/03/12
RVAForm S-8 Filed with SEC
02/03/12
RVAPresentation at Polymers in Medical Applications Conference
01/03/12
RVABriefing Call Telephone Number
01/03/12
RVAPreliminary Final Report
29/02/12PRICE SENSITIVE
RVAPresentations at Citi and ASX New York Conferences
23/02/12
RVANotice of Briefing Call
23/02/12
RVAClinical Trial Update
17/02/12PRICE SENSITIVE
RVAAppendix 3B
10/02/12
RVAPresentations at CRT and LDDR Conferences
01/02/12
RVAAppendix 4C - quarterly
31/01/12PRICE SENSITIVE
RVAAppendix 3B
20/01/12
RVAPresentation at J.P. Morgan Conference
11/01/12
RVAAmended Appendix 3B x 2
23/12/11
RVAREVA Commences Clinical Trial
22/12/11PRICE SENSITIVE
RVAExpansion of Facilities
25/11/11
RVAPresentation at Piper Jaffray Health Care Conference
22/11/11
RVAQuarterly Report on Form 10-Q
15/11/11PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Chaos reigns markets – so let's take stock of where we're at ahead of December

For many people, it feels like the world has been getting crazier each year since 2020 (or 2016.) It's likely to continue
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.